Stock-exchange announcement
For media and investors only

Issued: 29 February 2024, London UK

Statement: Zantac (ranitidine) litigation

GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court. The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK enquiries
Media: Tim Foley +44 (0) 20 8047 5502 (London)
        Dan Smith +44 (0) 20 8047 5502 (London)
        Kathleen Quinn +1 202 603 5003 (Washington DC)
        Lyndsay Meyer +1 202 302 4595 (Washington DC)

Investor Relations: Nick Stone +44 (0) 7717 618834 (London)
                   James Dodwell +44 (0) 20 8047 2406 (London)
                   Mick Readey +44 (0) 7990 339653 (London)
                   Josh Williams +44 (0) 7385 415719 (London)
                   Camilla Campbell +44 (0) 7803 050238 (London)
                   Steph Mountifield +44 (0) 7796 707505 (London)
                   Jeff McLaughlin +1 215 751 7002 (Philadelphia)
                   Frannie DeFranco +1 215 751 4855 (Philadelphia)

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in the company’s Annual Report on Form 20-F for 2022, and Q4 Results for 2023.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS